Opendata, web and dolomites

ENDFLU SIGNED

Evaluation of ratioNally Designed Influenza vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ENDFLU project word cloud

Explore the words cloud of the ENDFLU project. It provides you a very rough idea of what is the project "ENDFLU" about.

encoding    constructs    na    fusions    candidates    immunogenicity    induces    criteria    world    cell    india    protective    enter    mice    proteins    safety    either    human    conserved    scientific    vaccine    mediated    internal    indian    mva    worldwide    expertise    head    biochemical    select    infection    functional    biophysical    encode    manifestations    advocacy    rationally    create    epitopes    manufacturing    expressed    polyepitope    broadly    fueled    toward    clade    trial    chim    nanoparticles    influenza    m2e    seeds    designed    combined    gmp    formulation    compliant    ing    clinically    cross    repository    combination    dose    strategies    endflu    artificial    rational    construct    demonstration    pandemic    generation    achievements    optimize    assessing    hemagglutinin    adoption    stem    efficacy    protein    optimized    ferrets    clinical    elicit    combat    followed    complementary    immunity    humoral    plan    optimal    model    h5    surface    vaccination   

Project "ENDFLU" data sheet

The following table provides information about the project.

Coordinator
STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER 

Organization address
address: BUNTEWEG 2
city: HANNOVER
postcode: 30559
website: www.tiho-hannover.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 14˙444˙867 €
 EC max contribution 8˙646˙254 € (60%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER DE (HANNOVER) coordinator 1˙234˙225.00
2    CURVE CLINICAL BV NL (AMSTERDAM DUIVENDRECHT) participant 3˙364˙571.00
3    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 2˙342˙075.00
4    VIB BE (ZWIJNAARDE - GENT) participant 608˙750.00
5    UNIVERSITEIT UTRECHT NL (UTRECHT) participant 435˙707.00
6    LUNDS UNIVERSITET SE (LUND) participant 360˙925.00
7    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) participant 300˙000.00
8    COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH IN (NEW DEHLI) participant 0.00
9    INDIAN INSTITUTE OF SCIENCE IN (BANGALORE) participant 0.00
10    INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH THIRUVANANTHAPURAM IN (THIRUVANANTHAPURAM) participant 0.00
11    MANIPAL ACADEMY OF HIGHER EDUCATION IN (MANIPAL) participant 0.00
12    MYNVAX PRIVATE LIMITED IN (BANGLADORE) participant 0.00
13    SETH G S M COLLEGE AND K E M HOSPITAL DIAMOND JUBILEE SOCIETY IN (MUMBAI) participant 0.00
14    TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE IN (FARIDABAD) participant 0.00

Map

 Project objective

ENDFLU will develop three complementary next-generation influenza vaccination strategies for the world, fueled by the unique combined expertise of Indian and European partners in rational vaccine design and development: • Create a repository of pre-pandemic GMP-compliant MVA-based vaccine seeds, each encoding an influenza hemagglutinin (HA), based on European partners demonstration of clinical safety and cross-clade immunogenicity of MVA-H5. • Optimize and select protein- and MVA-based constructs developed by Indian and European ENDFLU partners, resulting in a rationally combined vaccine formulation that induces broadly protective humoral and cell-mediated immunity against all influenza manifestations. This will be advanced in a Phase I clinical trial and Controlled Human Infection Model (CHIM) study. • Pre-clinically advance other promising protein- and MVA-based constructs toward future development beyond ENDFLU. Constructs to elicit humoral immunity build on rationally-designed and optimized conserved epitopes of influenza surface proteins, HA stem- and HA head-nanoparticles, and NA-M2e fusions either as proteins or MVA expressed. Other MVA-based constructs to elicit cell-mediated immunity will encode conserved internal protein T cell epitopes, as an artificial polyepitope. The best candidates will be selected based on biochemical, biophysical, functional and manufacturing criteria, and immunogenicity and protective efficacy in mice and ferrets. The selected protein-based construct will enter a Part A Phase I clinical trial in India assessing safety, immunogenicity and optimal dose, to be combined with the selected MVA-based construct. This protein-MVA combination will enter a Part B Phase I clinical trial in the EU, assessing safety and immunogenicity, followed by the CHIM study. A dissemination and exploitation plan, and collaboration with key scientific advocacy organizations will facilitate the adoption of ENDFLU achievements to combat influenza worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENDFLU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENDFLU" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

HEAP (2020)

Human Exposome Assessment Platform

Read More  

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EXIMIOUS (2020)

Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome

Read More